W. Toro

An updated cost-utility model for onasemnogene abeparvovec (Zolgensma®) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER)

Rebecca Dean, I. Jensen, Phil Cyr et al. · Journal of Market Access & Health Policy · 2021 · 46 citations · Full text

Nusinersen for Spinal Muscular Atrophy in the United States: Findings From a Retrospective Claims Database Analysis

Marjolaine Gauthier‐Loiselle, Martin Cloutier, W. Toro et al. · Advances in Therapy · 2021 · 21 citations · Full text

Health Care Resource Utilization and Costs for Patients with Spinal Muscular Atrophy: Findings from a Retrospective US Claims Database Analysis

W. Toro, Min Yang, Mihaela Georgieva et al. · Advances in Therapy · 2023 · 12 citations · Full text